The Supreme Court has ruled in Pliva, Inc. v. Mensing, 131 S. Ct. 2567 (2011), that state-law failure-to-warn claims against generic drug manufacturers are preempted. The Court split 5-4 in ascertaining congressional intent; all nine justices agreed, however, that the outcome in this case “makes little sense.”
CCL’s Louis M. Bograd was lead counsel for respondents. The New York Times has early coverage.
Share »